Volume: 43 Issue: 1
Year: 2023, Page: 380-385, Doi: https://doi.org/10.51248/.v43i01.2295
Introduction and Aim: Breast cancer is the most prevalent sex-based malignancy worldwide. Nolvadex is commonly used as first-line therapy for patients with breast cancer. However, studies have indicated that long-term usage of this medicine can result in nephrotoxicity, which can damage kidney tissues. So, the aim of this research was to examine what happened to the serum levels of urea, uric acid, and creatinine when the drug was given to rats in a range of different doses.
Materials and Methods: Male Wistar rats (n=40) were randomly divided into four groups (n=10 each). The physiological solution (normal saline, 0.9%) was given to the control group (G1). Rats in Groups 2, 3, and 4 received Nolvadex at dosages of 30, 40, and 50 mg/kg of body weight four times weekly for a total of 10 weeks. At the end of the experimental period blood drawn from these animals were checked for serum concentrations of urea, uric acid, and creatinine. The animals were sacrificed and their kidneys subjected to histopathological examination. Data obtained was subjected to statistical analysis.
Results: The levels of urea, uric acid, and creatinine that were discovered in the experimental groups were all determined to be significantly higher than the levels that were discovered in the control group. In the experimental group that was given Nolvadex, an infiltration of inflammatory cells, blood congestion, pyknic and necrotic nuclei in the glomerulus, substantial epithelial deterioration in the renal tubules, and an altered renal tissue architecture were detected.
Conclusion: Serum levels of urea, uric acid and creatinine levels increased when experimental rats were administered with varying concentration of the drug Nolvadex. Its administration caused alteration to the architecture of renal tissue.
Keywords: Breast cancer; Nolvadex; Kidney; Urea; Uric acid; Creatinine.
1. Wilkinson, L., Gathani,T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.
2. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-249.
3. Weycker, D., Edelsberg, J., Kartashov, A., Barron, R., Lyman, G. Risk and healthcare costs of chemotherapy induced neutropenic complications in women with metastatic breast cancer. Chemotherapy. 2012; 58 (1): 8-18.
4. Zhao, F., Xie, P., Jiang, J., Zhang, L., An., W., Zhan, Y. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int. J Mol. Sci. 2014;15(3):4019-4030.
5. Shukla, J., Dinda, A.K., Srivastava, A.K., Srivastava, K., Mittal, B.R., Bandyopadhyay, G.P. Nano tamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nano tamoxifen. World. J.Nucl.Med.2016; 15(1):7-11.
6. Suddek, G.M. Protective role of thymoquinone against liver damage induced by tamoxifen in female rats. Can. J. Physiol. Pharmacol. 2014; 92(8):640-644.
7. Pandey, S.K., Ghosh, S., Maiti, P., Haldar, C. Therapeutic efficacy and toxicity of tamoxifen loaded nanoparticles for Breast cancer. Int. J. Biol. Macromol. 2015; 72:309-319.
8. Wolf, D., Jordan, V.C. Gynecologic complications associated with long-term adjuvant tamoxifen Therapy for breast cancer. Gynecol. Oncol. 1992; 45(2):118-128.
9. Paschos, P., Paletas, K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009; 13: 9-19.
10. Labbe, G., Pessayre, D., Fromenty, B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol.2008; 22: 335-353.
11. Lelliott, C.J., López, M., Curtis, R.K., Parker, N., Laudes, M., Yeo, G., et al., Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005; 19(9):1108-1119.
12. Bancroft, J.D., Steven, A.S. Theory, and practice of histological techniques. 2nd ed. Churchill Livingstone, Edinburgh. London.2012. 233-250.
13. Chong, W.C., Wu, R., Tu, A. Y. A study on tissue processing. Int. J. Res. 2012; 1:37-43.
14. Saleh, H., Mohamed, B., Marie, M.A.S. Sodium butyrate attenuates nephrotoxicity induced by tamoxifen in rats. J. Appl. Pharm. Sci. 2016; 6(06): 066-072.
15. Parlakpinar, H., Tasdemir, S., Polat, A., Bay-Karabulut, A., Vardi, N., Ucar, M., et al., Protective role of caffeic acid phenethyl ester (cape) on gentamicin-induced acute renal toxicity in rats. Toxicology, 2005; 207(2): 169-177.
16. Lien, E.A., Solheim, E., Ueland, P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991; 51:4837–4844.
17. Zuhair, Z. The role of vitamin C in alteration of enzymes responsible for energy metabolism induced by administration of tamoxifen to mice. Adv Biol Chem. 2011; 1(02): 15-23.
18. Nazarewicz, R.R., Zenebe, W.J., Parihar, A., Larson, S.K., Alidema, E., Choi, J., et al., Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007; 67:1282-1290.
19. Tabassum, H., Parvez, S., Rehman, H., Dev Banerjee, B., Siemen, D., Raisuddin, S. Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice. Hum. Exp. Toxicol. 2007; 26(6): 509-518.
20. Gabri, M. S., Osman, A. M., El-Sayed, M. M., Somaia, N. A. Prophylactic effect of tamoxifen against induction of mammary carcinoma. Egypt J Hosp Med. 2004; 14: 104-114.
21. Olufunsho, A., Alade, A. Investigation of lipid peroxidation as probable mechanism of rifampicin toxicity in vivo. Ann Neurosci. 2012; 19(2):68-70.
Adnan Fayadh Sameer, Marwa Abdulsalam Kader, Noor Sallih Hallab, Tahreer Hadi Saleh. Investigations into Nolvadex toxicity on the kidneys of albino male rats: Physiological and histopathological study. Biomedicine: 2023; 43(1): 380-385